Last updated: August 1, 2026
Delta-Cortef is an older oral corticosteroid brand containing prednisolone. Its commercial relevance is limited because treatment demand is supplied primarily by generic prednisolone products. No active, brand-specific Delta-Cortef clinical development program or meaningful current U.S. brand franchise is evident. The relevant market is generic oral prednisolone, not Delta-Cortef as a standalone product.
What is Delta-Cortef and what drug does it contain?
Delta-Cortef is a systemic glucocorticoid formulation of prednisolone. Prednisolone suppresses inflammation and immune activity through glucocorticoid-receptor signaling and is used across inflammatory, allergic, rheumatologic, dermatologic, respiratory, hematologic and autoimmune conditions.
Historical Delta-Cortef labeling described oral tablets in multiple strengths, including 5 mg, 10 mg and 20 mg presentations. The product was associated with The Upjohn Company, which later became part of Pfizer through corporate transactions. The historical brand should not be confused with:
- Delta-Cortef, prednisolone
- Cortef, hydrocortisone
- Deltasone, prednisone
- Medrol, methylprednisolone
Prednisolone and prednisone are closely related but are not identical active ingredients. Prednisone is converted in vivo to prednisolone, while prednisolone is already the active glucocorticoid.
Delta-Cortef product profile
| Attribute |
Delta-Cortef |
| Active ingredient |
Prednisolone |
| Therapeutic class |
Systemic glucocorticoid |
| Historical dosage form |
Immediate-release oral tablets |
| Historical strengths |
5 mg, 10 mg and 20 mg |
| Administration |
Oral |
| Primary use |
Systemic inflammatory and immune-mediated disorders |
| Original commercial association |
The Upjohn Company |
| Current market position |
Legacy brand; generic prednisolone is the relevant commercial market |
| Biologic |
No |
| Biosimilar exposure |
None |
| Current branded clinical program |
No identifiable active program |
What clinical trials have evaluated Delta-Cortef?
No modern clinical-trial program appears to be conducted under the Delta-Cortef brand. The product is a legacy prednisolone medicine, and its original approval predates the current ClinicalTrials.gov registration framework.
Clinical evidence relevant to Delta-Cortef comes from the broader prednisolone literature and from clinical use of systemic corticosteroids. Studies have evaluated prednisolone in conditions including:
- Asthma and acute respiratory exacerbations
- Pediatric nephrotic syndrome
- Rheumatoid and other inflammatory diseases
- Acute lymphoblastic leukemia treatment protocols
- Autoimmune and allergic disorders
- Ophthalmic and dermatologic inflammatory conditions
- Transplantation and immune-mediated disease
These trials generally evaluate prednisolone as an active ingredient, not Delta-Cortef as a branded product. Trial results therefore support the pharmacology and clinical use of prednisolone but do not establish a current commercial advantage for Delta-Cortef.
Clinical evidence and risk profile
Prednisolone has a well-established efficacy profile for short-term suppression of inflammation. The principal clinical risks are related to dose, duration and patient characteristics. FDA labeling identifies risks that include:
- Adrenal suppression
- Infection risk
- Hyperglycemia and diabetes worsening
- Hypertension and fluid retention
- Osteoporosis
- Cataracts and glaucoma
- Psychiatric effects
- Gastrointestinal complications
- Growth suppression in pediatric patients
- Withdrawal-related adrenal insufficiency after prolonged use
The main clinical development limitation is not lack of efficacy. It is the absence of meaningful differentiation from generic prednisolone and competing systemic corticosteroids.
What is the FDA status of Delta-Cortef?
Delta-Cortef is not a current growth-stage FDA product. The relevant U.S. regulatory position is historical approval and generic substitution rather than active branded innovation.
The FDA-approved prednisolone label established the drug’s indications, contraindications, warnings, precautions and dosing framework. Generic prednisolone products are approved through abbreviated new drug applications and generally rely on reference-product equivalence rather than new efficacy trials.
FDA regulatory characteristics
| Regulatory issue |
Assessment |
| New molecular entity status |
No |
| New drug development opportunity |
Low |
| Approval pathway for current competitors |
ANDA or other abbreviated pathway |
| Required modern efficacy program |
Generally no for therapeutically equivalent generics |
| Pediatric exclusivity opportunity |
Not associated with the legacy brand |
| Orphan-drug exclusivity |
Not applicable to the legacy product |
| Current branded indication expansion |
No identifiable program |
| Regulatory differentiation |
Limited |
The product’s regulatory value is therefore tied to manufacturing authorization, supply reliability and portfolio economics rather than to clinical innovation.
What is the Orange Book status of Delta-Cortef?
Delta-Cortef has no meaningful current Orange Book exclusivity position. Any historical patents, approvals or brand rights associated with the product do not create a present-day barrier to generic prednisolone competition.
For legacy products, the Orange Book may distinguish between active listings and discontinued products. A discontinued status does not necessarily mean that the active ingredient lacks FDA-approved generic products. It means the branded product is no longer marketed or is no longer listed as an active commercial reference in the same way as a currently marketed product.
Exclusivity and patent position
| Protection category |
Delta-Cortef assessment |
| Active composition-of-matter patent |
None expected |
| Active formulation patent |
None identified |
| Active method-of-use patent |
None identified |
| Regulatory exclusivity |
Expired |
| Pediatric exclusivity |
Expired or not applicable |
| Orphan exclusivity |
Not applicable |
| Paragraph IV exposure |
No meaningful branded Delta-Cortef dispute expected |
| Generic substitution barrier |
Low |
Because prednisolone has been marketed for decades, any original composition and product patents have expired. The commercial market is open to multiple generic manufacturers.
Are there Paragraph IV challenges or patent lawsuits involving Delta-Cortef?
No significant current Paragraph IV litigation involving Delta-Cortef is evident. The brand’s protection period is too old to support a conventional current generic-entry dispute.
Paragraph IV litigation is more relevant to newer dosage forms, combination products or reformulated corticosteroids. A generic applicant may certify against patents listed for a current reference product, but that framework does not create a material defense for the discontinued Delta-Cortef brand.
Litigation and settlement assessment
| Issue |
Current assessment |
| Delta-Cortef patent litigation |
No significant active dispute identified |
| Generic launch litigation |
Unlikely for the legacy brand |
| Settlement agreements |
No material Delta-Cortef settlement identified |
| Patent-term extension |
Not relevant |
| Regulatory exclusivity dispute |
None identified |
| Manufacturing litigation risk |
Possible at supplier level, not brand-specific |
How large is the Delta-Cortef market?
There is no meaningful standalone Delta-Cortef market to measure. Public pharmaceutical-market datasets generally report prednisolone products by active ingredient, dosage form and manufacturer rather than by a discontinued historical brand.
The commercial market is best analyzed as oral generic prednisolone. It is a mature, low-price, multi-supplier market with demand driven by clinical use rather than brand promotion.
Market structure
Generic prednisolone competes with:
- Generic prednisone
- Methylprednisolone tablets and dose packs
- Dexamethasone
- Hydrocortisone
- Prednisolone oral solutions
- Specialty formulations for pediatric and ophthalmic use
Prednisolone retains clinical demand where physicians prefer the active drug directly, where pediatric dosing requires liquid formulations, or where specific clinical protocols use prednisolone rather than prednisone.
Commercial characteristics
| Market factor |
Impact on Delta-Cortef opportunity |
| Generic competition |
Strongly negative |
| Brand loyalty |
Minimal |
| Pricing power |
Very low |
| Prescriber promotion |
Limited |
| Formulation differentiation |
Potentially relevant only for new products |
| Supply-chain importance |
High |
| Reimbursement pressure |
High |
| Switching risk |
High |
| New indication opportunity |
Low without differentiated delivery or evidence |
The main commercial risks are price erosion, wholesaler concentration, manufacturing interruptions and substitution by prednisone or other corticosteroids.
What formulations are protected in the prednisolone market?
The historical Delta-Cortef tablet does not have a defensible modern formulation moat. Commercial differentiation in prednisolone is more likely to arise from dosage form and administration convenience.
Potentially differentiated categories include:
Oral liquids
Prednisolone sodium phosphate and prednisolone acetate oral liquids are important in pediatric and swallowing-impaired populations. Taste, preservative system, concentration, dosing device and stability can influence product selection.
Orally disintegrating or pediatric formulations
Products that reduce swallowing burden or improve dose accuracy may obtain commercial differentiation, although formulation patents must be evaluated individually. These products compete on usability rather than on the underlying prednisolone molecule.
Ophthalmic products
Prednisolone ophthalmic suspensions and solutions are separate dosage-form markets. Their regulatory and formulation issues include particle size, sterility, suspension uniformity, preservative systems and ocular tolerability.
Modified-release products
A modified-release prednisolone product could create a stronger intellectual-property position if it demonstrated clinically meaningful pharmacokinetic or adherence benefits. Delta-Cortef itself has no identified modified-release platform.
How does Delta-Cortef compare with prednisone and methylprednisolone?
| Attribute |
Prednisolone / Delta-Cortef |
Prednisone |
Methylprednisolone |
| Active drug |
Prednisolone |
Prednisone, converted to prednisolone |
Methylprednisolone |
| Generic availability |
Broad |
Broad |
Broad |
| Brand relevance |
Legacy |
Legacy and generic |
Legacy and generic |
| Pediatric liquid availability |
Important market segment |
More limited in some markets |
Limited relative to prednisolone |
| Relative mineralocorticoid activity |
Present |
Present after conversion |
Lower than prednisone/prednisolone |
| Differentiation |
Mainly dosage form and clinical preference |
Cost and familiarity |
Pharmacologic profile and dosing preference |
| Patent barrier |
None for the legacy brand |
None for legacy products |
None for legacy products |
| Market risk |
Price erosion and substitution |
Price erosion and substitution |
Price erosion and substitution |
Prednisolone may have an advantage over prednisone in patients who require the active compound directly, including some pediatric and hepatic-impairment settings. Methylprednisolone may be preferred when lower mineralocorticoid activity is clinically desirable.
What is the 2025–2030 market projection for Delta-Cortef?
Delta-Cortef itself has a flat-to-declining outlook because it is a legacy brand without identifiable exclusivity, clinical development or differentiated formulation. The broader prednisolone market should remain clinically durable but commercially constrained.
Projection by market segment
| Segment |
2025–2030 outlook |
Main driver |
| Delta-Cortef branded tablets |
Declining or negligible |
Discontinuation and generic substitution |
| Generic prednisolone tablets |
Stable to low growth |
Persistent clinical demand |
| Generic prednisolone oral liquids |
Stable to moderate growth |
Pediatric and administration needs |
| Prednisolone ophthalmic products |
Stable, competitive |
Ophthalmic procedure and inflammatory use |
| Novel modified-release prednisolone |
Uncertain, potentially higher value |
Requires clinical and formulation differentiation |
| Hospital and institutional supply |
Stable but price-sensitive |
Protocol-driven demand |
Base-case projection
The base case assumes:
- No relaunch of Delta-Cortef as a differentiated brand.
- Continued availability of generic prednisolone.
- No major new patent-protected prednisolone delivery system.
- Stable use of systemic corticosteroids across established indications.
- Continued substitution among prednisolone, prednisone and methylprednisolone.
Under this scenario, Delta-Cortef brand revenue remains immaterial. Generic prednisolone volume is likely to be stable, while nominal pricing remains under pressure. Any growth in total prescription volume would not necessarily translate into higher manufacturer revenue because generic price competition would absorb much of the increase.
Upside scenario
An investor or manufacturer could create a higher-value opportunity through:
- A better-tolerated pediatric liquid
- A preservative-free or low-excipient formulation
- An orally disintegrating product
- A device-enabled dosing system
- A modified-release formulation with demonstrated clinical value
- A supply-reliable product for shortage-prone channels
These opportunities would represent new prednisolone products, not a revival of the historical Delta-Cortef tablet.
Downside scenario
The main downside factors are:
- Further price compression
- Supplier consolidation
- Hospital formulary substitution
- Manufacturing interruptions
- Increased use of alternative corticosteroids
- Reduced branded-product reimbursement
- Regulatory or quality failures affecting a generic supplier
What generic launch risks exist for Delta-Cortef?
Generic launch risk is low in the traditional patent sense because the product has no meaningful remaining exclusivity. The principal risks concern commercial execution.
A new generic entrant would face:
- Established manufacturers with approved products
- Low reimbursement ceilings
- Pharmacy-benefit substitution
- Limited prescriber attachment to the Delta-Cortef name
- Contracting requirements with wholesalers and group purchasing organizations
- Manufacturing and quality-control requirements
- Low tolerance for supply interruptions
- Limited ability to command a premium
The strongest entry position would likely be a differentiated liquid, a reliable institutional-supply product or a formulation with clear administration advantages.
How strong is the Delta-Cortef patent estate?
The Delta-Cortef patent estate is commercially weak. The active ingredient is old, the brand is legacy-based, and the product has no apparent remaining composition, formulation or regulatory exclusivity.
Patent strength should be assessed as follows:
| Patent dimension |
Strength |
| Composition of matter |
None |
| Basic tablet formulation |
None |
| Method of use |
None likely to remain enforceable |
| Delivery technology |
None linked to Delta-Cortef |
| Manufacturing process |
Limited commercial blocking value |
| Geographic exclusivity |
None of strategic importance |
| Freedom to operate for generics |
Broad, subject to product-specific review |
Manufacturing know-how can still affect product quality and supply reliability, but it is not equivalent to a blocking patent estate.
Key Takeaways
- Delta-Cortef is a legacy prednisolone brand, not an active clinical-development asset.
- No current Delta-Cortef-specific clinical trial program is evident.
- Clinical evidence comes from prednisolone studies and longstanding corticosteroid use.
- Original patent and regulatory exclusivity have expired.
- No significant current Paragraph IV litigation or brand-specific settlement activity is evident.
- The relevant commercial market is generic oral prednisolone and related corticosteroids.
- Generic prednisolone demand should remain durable through 2030, but pricing power should remain weak.
- The strongest commercial opportunities are in pediatric liquids, administration devices, ophthalmic products and differentiated delivery systems.
- Delta-Cortef itself has negligible projected growth without a new branded relaunch and a differentiated formulation.
FAQs
Is Delta-Cortef still available in the United States?
Delta-Cortef is a historical brand. Current prescriptions are generally supplied through generic prednisolone products rather than the original brand.
Is Delta-Cortef the same as prednisone?
No. Delta-Cortef contains prednisolone. Prednisone is converted into prednisolone in the body, but the two products are separate active ingredients.
Can generic manufacturers launch prednisolone without a Delta-Cortef patent license?
Expired legacy protection generally does not require a license. A manufacturer must still satisfy FDA approval, bioequivalence, manufacturing and labeling requirements.
Does Delta-Cortef have biosimilar competition?
No. Prednisolone is a chemically synthesized small molecule, not a biologic. Competition occurs through generic-drug pathways, not biosimilar approval.
Could a new prednisolone formulation support premium pricing?
Yes, but only if it provides measurable clinical or administration value, such as improved pediatric acceptability, dosing accuracy, stability, tolerability or pharmacokinetic performance.
References
- DailyMed. (n.d.). Prednisolone tablet prescribing information. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. National Institutes of Health.
- U.S. Food and Drug Administration. (n.d.). Prednisolone product labeling and regulatory information. FDA.
